Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F13%3A00103188" target="_blank" >RIV/00843989:_____/13:00103188 - isvavai.cz</a>
Alternative codes found
RIV/61988987:17110/13:A14019UJ RIV/00216208:11110/13:10196446
Result on the web
<a href="http://dx.doi.org/10.1016/j.leukres.2013.03.006" target="_blank" >http://dx.doi.org/10.1016/j.leukres.2013.03.006</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.leukres.2013.03.006" target="_blank" >10.1016/j.leukres.2013.03.006</a>

Result language
angličtina
Original language name
Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma
Original language description
Histone deacetylases (HDACs) mediate protein acetylation states, which in turn regulate normal cellular processes often dysregulated in cancer. These observations led to the development of HDAC inhibitors that target tumors through multiple effects on protein acetylation. Clinical evidence demonstrates that treatment with HDAC inhibitors (such as vorinostat, panobinostat, and romidepsin) in combination with other antimyeloma agents (such as proteasome inhibitors and immunomodulatory drugs) has promisingantitumor activity in relapsed/refractory multiple myeloma patients. This mini-review highlights the role of protein acetylation in the development of cancers and the rationale for the use of HDAC inhibitors in this patient population.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)